Editor-in-Chief Oncotarget

Mikhail Blagosklonny

Mikhail (Misha) V. Blagosklonny, MD, Ph.D. Professor of Oncology at Roswell Park Cancer Institute, Buffalo, NY, USA. His research interests range from molecular and cellular biology to clinical investigations and specifically include oncogenes and tumor suppressors, signal transduction, cell cycle, mitosis, apoptosis, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies such as exploiting cancer cell cycling and drug resistance for selective protection of normal cells. He has extended this approach to other age-related diseases and aging itself, thus revealing anti-aging drugs such as rapamycin to be used today (Cell Cycle, 2006, 5 : 2087 - 2102). He is an author of hyper-function theory of aging as well as anti-cancer approaches know as chemotherapeutic engineering and cell cyclotherapy.

Dr. Blagosklonny published 300 research articles, reviews and book chapters. He is the Founding Editor and Editor-in-Chief of Cell Cycle and also Co-editor and co-founder of Aging, Oncotarget and Oncoscience. He serves or has served as an Associate Editor for Cancer Biology & Therapy, Autophagy, Cancer Research, Cell Death and Differentiation, International Journal of Cancer, The American Journal of Pathology and PLOS ONE.

https://www.crunchbase.com/person/mikhail-blagosklonny#section-overview

When public speak of today’s medicine, precision plays one of the most significant roles and people’s lives are literally dependent on it. Likewise, any researches related to medicine are necessary to meet the top standards. The challenge nowadays is that any conclusions of researches can be published online and used as a reference without being thoroughly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and attempted to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality measure. That assists both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website demonstrates a full publications list with respective scores higher than 100 as well as reports mentioned previously. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it provides the required help to anyone, who has interest in oncology.
Oncotarget
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This paper was published back in 2018 by Oncotarget and written by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The publication has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Likewise, the publication about melanoma, was used for citations in various news articles 69 times. Besides that, it was mentioned in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a short overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is happy to have the chance to share with online viewers this highly appreciated and top-quality information, that is trustworthy and reliable.
http://vivo.med.cornell.edu/display/person623769

Comments

  1. AnonymousDecember 22, 2022 at 10:50 PM

    Het artikel is echt geweldig, bedankt! Kun je ook iets schrijven over software ontwikkelaar?

    ReplyDelete

Post a Comment

Popular posts from this blog

Professor of Oncology

Image
Mikhail Blagosklonny Professor of Oncology, RPCI and Editor-in-Chief, Oncotarget Verified email at oncotarget.com https://scholar.google.com/citations?user=REO9YogAAAAJ&hl=en Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 G Kroemer, L Galluzzi, P Vandenabeele, J Abrams, ES Alnemri, ... Cell death & differentiation 16 (1), 3-11 3039 2009 Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 L Galluzzi, I Vitale, JM Abrams, ES Alnemri, EH Baehrecke, ... Cell Death & Differentiation 19 (1), 107-120 2316 2012 Stabilization of wild-type p53 by hypoxia-inducible factor 1α WG An, M Kanekal, MC Simon, E Maltepe, MV Blagosklonny, LM Neckers Nature 392 (6674), 405-408 995 1998 Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 L Galluzzi, I Vitale, SA Aaronson, JM Abrams, D Adam, P Agostinis, ... Cell Death & Differentiation...
Read more

From rapalogs to anti-aging formula

Image
From rapalogs to anti-aging formula Mikhail V. Blagosklonny Go to: Abstract Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin slows aging and extends life span in a variety of species from worm to mammals. Rapalogs can prevent age-related diseases, including cancer, atherosclerosis, obesity, neurodegeneration and retinopathy and potentially rejuvenate stem cells, immunity and metabolism. Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor. Rational combinations of these drugs with physical exercise and an anti-aging diet (Koschei formula) can maximize their anti-aging effects and decrease side effects. Keywords:  lifespan, longevity, rejuvenation, health, diseases At first, the discovery of anti-aging p...
Read more